Executive Summary: The selection of vector components: including capsid, promoter, and plasmid backbone: directly informs the regulatory trajectory and risk profile of an Advanced Therapy Medicinal Product (ATMP). Early, data-driven decisions on these elements are a primary determinant of Chemistry, Manufacturing, and Controls (CMC) readiness and are foundational to a successful Investigational New Drug (IND) application. A proactive design strategy mitigates downstream manufacturing and safety hurdles.

Aligning Vector Architecture with Regulatory Expectations

The architecture of a viral vector is a foundational pillar of any successful ATMP program. Decisions made during the design phase have cascading effects on manufacturability, in vivo activity, and the overall safety profile presented to regulatory bodies. A program’s viability is often determined by how well these initial design inputs anticipate the rigorous scrutiny of a CMC data package.

The interplay between vector elements requires a systematic approach to optimization. As demonstrated in studies evaluating numerous promoter and enhancer combinations for therapeutic protein expression, minor changes to the expression cassette can yield significant differences in potency and immunogenicity (PMID: 28056565). This same principle applies to capsid selection, where evaluating multiple serotypes is necessary to identify a candidate with the optimal balance of tissue specificity and a favorable immune profile. Strategic Design Guidance Accelerating Development Lifecycles.

From Plasmid to Product: A Manufacturing-Forward Approach

The transition from research-grade material to a GxP-compliant manufacturing process begins with the source plasmids. A robust plasmid backbone, free of cryptic sequences and optimized for high-yield production, de-risks process development and ensures batch-to-batch consistency. This focus on manufacturing readiness from day one is a key attribute of programs that successfully navigate the typical 18-24 month timeline to IND.

Our scientific continuity and deep operational expertise are built on a legacy of vector innovation. As one partner noted, this allows for a seamless transition from early-stage research to IND-enabling development:

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… Franklin Biolabs is the key scientific partner for our AAV-vector based gene therapy candidate development.”

This continuity, supported by our >100,000 sq ft of dedicated laboratory and study space, ensures that vector design choices are always made with a clear line of sight to scalable manufacturing and regulatory acceptance. This approach has been validated by a 100% IND approval success rate for programs supported since 2019, with the Franklin Biolabs brand formally launching in 2024 to carry this legacy forward.